Korean Post-marketing Surveillance for Kombiglyze XR®

Study identifier:CV181-306

ClinicalTrials.gov identifier:NCT01754142

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

Kombiglyze XR (Saxagliptin + Metformin XR Fixed Dose Combination) Regulatory Postmarketing Surveillance

Medical condition

Diabetes Mellitus, Type 2

Phase

N/A

Healthy volunteers

No

Study drug

-

Sex

All

Actual Enrollment

755

Study type

Observational

Age

18 Years +

Date

Study Start Date: 24 Nov 2012
Primary Completion Date: 01 Sept 2016
Study Completion Date: 01 Sept 2016

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Aug 2017 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria